These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 4789495)
1. [Studies of the effect of I-adamantyl-amine hydrochloride and of L-dopa with Ro 4-4602 in human catatonia]. Megna GF; Specchio LM Acta Neurol (Napoli); 1973; 28(5):566-72. PubMed ID: 4789495 [No Abstract] [Full Text] [Related]
2. [Iron, transferrin, copper and ceruloplasmin of the serum and cerebrospinal fluid in extrapyramidal diseases and primary myopathies. Study in basic conditions and in Parkinsonism after treatment with dopaminergic agents (L-dopa, L-dopa + RO 4-4602, amantadine)]. Campanella G; Carrieri P; Romito D; Pasqual-Marsettin E Acta Neurol (Napoli); 1973; 28(1):1-34. PubMed ID: 4704396 [No Abstract] [Full Text] [Related]
3. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor]. Lombardo L; de la Garza R; Ivan-Reynoso G Arch Invest Med (Mex); 1974; 5(2):105-16. PubMed ID: 4433198 [No Abstract] [Full Text] [Related]
4. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results]. De Divitiis E; Cerillo A; Tata MR; Decina A Acta Neurol (Napoli); 1973; 28(2):208-12. PubMed ID: 4709076 [No Abstract] [Full Text] [Related]
5. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor]. Streifler M; Vardi J; Kesten M Harefuah; 1972 Nov; 83(9):362-4. PubMed ID: 4669737 [No Abstract] [Full Text] [Related]
6. [Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)]. Steinhäusl H Wien Med Wochenschr; 1973 Jun; 123(26):433-5. PubMed ID: 4578743 [No Abstract] [Full Text] [Related]
7. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)]. Gehlen W; Eisenlohr JJ Nervenarzt; 1974 Jan; 45(2):22-9. PubMed ID: 4601993 [No Abstract] [Full Text] [Related]
8. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)]. Puca FM; Megna GF; Masi G; Specchio LM Riv Patol Nerv Ment; 1974 Oct; 95(5):676-84. PubMed ID: 4470268 [No Abstract] [Full Text] [Related]
9. Bensarazid with L-dopa in the treatment of parkinson's disease. Van Wieringen A S Afr Med J; 1974 Feb; 48(6):206-9. PubMed ID: 4814495 [No Abstract] [Full Text] [Related]
10. [Decarboxylase inhibitor given in combination with l-dopa. A new therapeutic principal in parkinsonism]. Dietrichson P Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2113-5. PubMed ID: 4590070 [No Abstract] [Full Text] [Related]
11. [The association of L-DOPA and Ro 4-4602 in the treatment of Parkinson's disease (author's transl)]. Campanella G; Pennetta R Riv Patol Nerv Ment; 1974 Oct; 95(5):673-5. PubMed ID: 4470267 [No Abstract] [Full Text] [Related]
12. Letter: Treatment of Huntington's chorea. Candelise L; Faglioni P; Spinnler H; Vignolo LA N Engl J Med; 1973 Nov; 289(22):1201. PubMed ID: 4271092 [No Abstract] [Full Text] [Related]
13. Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602). Chouza C; Romero S; Gomensoro JB Acta Neurol Latinoam; 1974; 20(1-4):116-38. PubMed ID: 4619960 [No Abstract] [Full Text] [Related]
14. L-dopa and amantadine hydrochloride in Parkinson's disease. Parkes JD; Zilkha KJ; Knill-Jones RP; Clements PJ; Baxter R Int Z Klin Pharmakol Ther Toxikol; 1971 Apr; 4(3):356-60. PubMed ID: 4931417 [No Abstract] [Full Text] [Related]
15. The effect of anti-Parkinson drugs on catalepsy induced by -methyl-p-tyrosine in rats pretreated with intraventricular 6-hydroxydopamine. Cashin CH; Sutton S Br J Pharmacol; 1973 Mar; 47(3):658P-659P. PubMed ID: 4738385 [No Abstract] [Full Text] [Related]
16. [Effect of a decarboxylase inhibitor (Ro 4-4602) in combination with L-dopa on inhibited depressions]. Matussek N; Benkert O; Schneider K; Otten H; Pohlmeier H Arzneimittelforschung; 1970 Jul; 20(7):934-5. PubMed ID: 4918921 [No Abstract] [Full Text] [Related]
17. The effect of L-5-hydroxytryptophan alone and in combination with a decarboxylase inhibitor (Ro-4-4602) in depressive patients. Matussek N; Angst J; Benkert O; Gmür M; Papousek M; Rüther E; Woggon B Adv Biochem Psychopharmacol; 1974; 11(0):399-404. PubMed ID: 4602669 [No Abstract] [Full Text] [Related]
18. L-dopa treatment of parkinsonism. Clinical observations on the use of amantadine hydrochloride. Reveno WS; Bauer RB; Rosenbaum H Geriatrics; 1971 Aug; 26(8):61-70. PubMed ID: 5096462 [No Abstract] [Full Text] [Related]
19. [Treatment of the parkinsonian syndrome with L-dopa and amantadine]. Pendefunda GH; Pollingher B; Stefanache F; Gavril A; Oprişan C; Merling M; Nemţeanu E; Ciuntu M; Koropitzer I Neurol Psihiatr Neurochir; 1973; 18(6):559-68. PubMed ID: 4790488 [No Abstract] [Full Text] [Related]
20. [Dopaminergic control of the diencephalo-pituitary axis for somatotropin secretion]. Cavagnini F; Pontiroli AE; Raggi U; Peracchi M; Malinverni A Folia Endocrinol; 1973 Dec; 26(6):483-9. PubMed ID: 4801258 [No Abstract] [Full Text] [Related] [Next] [New Search]